Discover more of our free reports coverage from other companies within the Drugs - Generic industry. Pro-TD has currently selected Allergan PLC (NYSE: AGN) for due-diligence and potential coverage as ...

EAST HANOVER, N.J., Aug. 17 -- Reclast(R) (zoledronic acid) Injection has been approved by the US Food and Drug Administration as the first and only once-yearly medicine for postmenopausal ...

- Single infusion of Reclast increases bone mass for two years in postmenopausal women with osteopenia, a condition that can lead to osteoporosis(1) - Approximately 22 million women in US have ...

Dr. Reddy’s Laboratories announced the launch of Zoledronic Acid Injection, the generic version of Novartis‘ Reclast.

Reclast is also indicated to increase bone mass in men with osteoporosis; for the treatment of Paget's disease of bone (men and women); and for the treatment and prevention of glucocorticoid-induced ...

Dr. Reddy’s Laboratories (DRL) has launched Zoledronic Acid injection (5 mg/100 ml), a therapeutic equivalent generic version of Reclast injection, in the U.S. markets on Wednesday. The launch follows ...

Pharma major Dr Reddy’s Laboratories Ltd has launched Zoledronic Acid injection, a generic version of Reclast injection in the US market. It is generally indicated for the treatment of osteoporosis.

* Announced u.s. Launch of zoledronic acid injection, 5 mg/100 ml single dose vial, a generic version of novartis' reclast® injection * Mylan NV - received final approval from u.s. Fda for its ...